A securities class action is pending against Mereo, with an alleged class period from June 5, 2023 through December 26, 2025. The complaint alleges the company made repeated statements that setrusumab-driven bone mineral density gains would translate into reduced fracture rates in osteogenesis imperfecta patients. It also alleges Mereo cited Phase 2 results including a 67% reduction in annualized fracture rate, while omitting that the data lacked control-group comparisons needed to establish causation. The suit further alleges management knew the Phase 2 results could not distinguish setrusumab’s effects from changes due to standard of care or placebo effects. A court deadline to apply for lead plaintiff appointment has been set for April 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603180905PR_NEWS_USPR_____NY12987) on March 18, 2026, and is solely responsible for the information contained therein.